A Quiet Note to the Biomedical and Clinical Journal Editors: Process, Not Pressure, Is Your Only Shield

Retraction is being deweaponized. Those who struggle to maintain bias enforcement do not belong in academic or clinical publishing.

Barely two weeks after Autoimmunity published a quantitatively detailed study on residual plasmid DNA in modRNA COVID‑19 vaccine vials, Taylor & Francis confirmed it is “investigating concerns raised on PubPeer” and placed the paper under an online “investigation” banner. The study’s claims are plain and citable: 32 vials from 16 lots, Qubit fluorometry and qPCR, fragment sizing by nanopore, with SV40 promoter‑enhancer sequences detected in Pfizer vials. You do not have to agree with the interpretation to recognize that the methods, targets, and numeric outputs are specific and falsifiable—and already part of the scholarly record. Retraction Watch

Here is the problem you now own. COPE’s guidance reserves editorial badges of suspicion for defined concerns of a major nature (e.g., data integrity, undisclosed ethics issues), and it calls for transparent notices that explain what is at issue and why. Taylor & Francis’ own policy adds a second brake: expressions of concern are permanent and must be used sparingly. What triggered your banner, by your public account, was not a documented breach—but post‑publication chatter. That is not a scientific standard; it is an optics standard. And optics do not hold up in discovery. Publication Ethics

Meanwhile, the external environment has shifted under your feet. The U.S. Health and Human Services Secretary, Robert F. Kennedy Jr., has publicly warned the major journals, labeling certain editorial practices as corrupt and stating he may prohibit federal scientists from publishing in top titles. You may bristle at the rhetoric; the point is simpler: the warning is on the record, unmistakable, and directed at journals. Pretending it was never issued will not make it go away. The Washington Post

At the same time, the Department of Justice will likely begin to treat collusive suppression in knowledge markets as a competition problem. In July, DOJ filed a Statement of Interest in litigation over the Trusted News Initiative, emphasizing that antitrust law protects viewpoint competition in news markets. That filing is not about your journal—but it signals federal attention to the very fact pattern you now risk emulating if editorial actions are driven by off‑platform pressure rather than articulated methodological faults. You do not need a subpoena to understand what “adjacent fact patterns” means. Department of Justice

None of this is an argument to canonize the paper. It is an argument to respect process so thoroughly that your decision is unimpeachable on review. If there are methodological faults, name them precisely and publicly: primer design, standards, RNase controls, Qubit crosstalk corrections, lot custody, or VAERS‑linkage reasoning. Invite a formal comment; publish the authors’ response; have the exchange peer‑reviewed. If, after that, the work fails, retract it with a fully specified rationale. If it stands, let it stand. That is what editorial independence looks like when the room gets loud. (COPE will back you for doing exactly that.) Publication Ethics

The alternative—minor problems, anonymous allegations, online chatter, differences of interpretion (all vague banners), and silence about the concrete “concerns”—creates an evidentiary trail of viewpoint‑selective enforcement. That is the one narrative you do not want to underwrite: that high‑impact papers earn special post‑publication hurdles not applied to low‑impact ones. In the current climate, it reads like coordination even when it isn’t, and it invites precisely the scrutiny journals have long hoped to avoid. Taylor & Francis Newsroom

What correction looks like, today:

1. Specify the charge. Publish the exact charges of fraud or methodological claims under review. If something like PubPeer comments triggered the process, invite a round of submitted discourse from the critic and the authors. Then, identify the substantive issues you consider material; ignore ad hominem and off‑topic noise, and avoid two main traps: “problems” already addressed by the paper, and falling for molehills as mountains. Retraction Watch

2. Seek the rebuttal. Give the authors a short, defined window to respond point‑by‑point with data, raw files as appropriate, and protocol clarifications.

3. Referee the exchange. Send both the critique and the response to independent referees with relevant bench expertise (plasmid quantification; qPCR assay design; fluorometric interference; nanopore read handling).

4. Decide in daylight. Publish the outcome as a signed editorial with references to the specific defects found (or not found). If an expression of concern is warranted, align every sentence with COPE text and your own policy—and be prepared to remove it if the concerns do not hold. Publication Ethics

A final, quiet reminder. HHS leadership has already put journals on public notice. DOJ has likely by now moved into adjacent fact patterns about collusive suppression in the marketplace of ideas. If what you publish today looks like pre‑judgment by proxy, it will not age well and you invite a damaged reputation, a letter from the AG office and fewer opportunities to publish. If, instead, you slow down and apply the same due‑process template you’d apply to a paper with “comfortable” conclusions, you will have nothing to fear from anyone—because your record will defend itself.

Related:

Prediction: "They will try to retract our work"